Abgenix Introduces Enhanced Version of XenoMouse Technology
FREMONT, Calif. Dec. 4, 2001--Abgenix, Inc. announced today at the IBC Antibody Engineering Conference in San Diego, Calif., the launch of new versions of XenoMouse® mice that produce fully human monoclonal antibodies that contain both lambda and kappa light chains. Other transgenic mouse technologies in the commercial sector make human antibodies that contain only kappa light chains. Abgenix expects these strains of mice, making both human IgG kappa and human IgG lambda monoclonal antibodies, to expand significantly the number and diversity of XenoMouse-derived antibody product candidates for its collaborators and for itself.
The purpose of adding the human Ig lambda(lambda light chain genes) to XenoMouse strains of mice is to capture and to mimic more completely the full repertoire of the human antibody response. Approximately 40% of human antibodies have lambda light chains (Ig lambda) and the other 60% have kappa light chains (Ig kappa). Building on the foundation of the previous versions of XenoMouse mice, these new transgenic mice possess the complete immunoglobulin gene locus for making human lambda light chain antibodies in addition to genes encoding human heavy chain antibodies and human kappa light chain antibodies.
Introduction of the complete lambda light chain locus, containing 30 functional V genes, by Abgenix scientists extends the earlier achievement of Dr. Marianne Bruggemann of the Babraham Institute in the United Kingdom. Bruggemann previously generated a transgenic mouse bearing approximately half of the human lambda light chain locus and demonstrated that these genes were functional. Abgenix licensed the lambda light chain genes and obtained certain related materials from the Medical Research Council of the United Kingdom to make this new strain of XenoMouse animals.
Abgenix's XenoMouse technology involves transgenic mouse strains that possess an immune system in which the mouse antibody-producing genes have been inactivated and functionally replaced by most of the human antibody-producing genes. The XenoMouse animal's immune system still recognizes human antigens as foreign, but instead of producing mouse antibodies it produces fully human antibodies. Abgenix has developed multiple strains of XenoMouse mice that produce different classes of IgG antibodies (IgG1, IgG2, IgG4) for optimally choosing the antibody product candidate to a given disease indication.
Abgenix's XenoMax(TM) technology allows researchers to rapidly scan the majority of the immune repertoire of an immunized XenoMouse animal, and to identify B-cells that produce antibodies with the desired functional properties and the optimum affinities. Using rapid microplate-based assays to measure and rank antibodies according to design goals (e.g., potency, affinity, specificity), individual B-cells producing extremely high-quality antibodies can be identified and the antibody encoding genes recovered. XenoMax technology bypasses the generation of hybridomas and speeds product development timelines by allowing researchers to move directly into pre-clinical assessment of panels of suitable recombinant candidate antibody products, each ready for manufacturing scale-up.
Other news from the department science
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.
Most read news
More news from our other portals
See the theme worlds for related content
Topic world Antibodies
Antibodies are specialized molecules of our immune system that can specifically recognize and neutralize pathogens or foreign substances. Antibody research in biotech and pharma has recognized this natural defense potential and is working intensively to make it therapeutically useful. From monoclonal antibodies used against cancer or autoimmune diseases to antibody-drug conjugates that specifically transport drugs to disease cells - the possibilities are enormous
Topic world Antibodies
Antibodies are specialized molecules of our immune system that can specifically recognize and neutralize pathogens or foreign substances. Antibody research in biotech and pharma has recognized this natural defense potential and is working intensively to make it therapeutically useful. From monoclonal antibodies used against cancer or autoimmune diseases to antibody-drug conjugates that specifically transport drugs to disease cells - the possibilities are enormous
